# A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

> **NCT03733925** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Private Limited** · enrollment: 100 (actual)

## Conditions studied

- Spondylitis, Ankylosing
- Arthritis, Psoriatic

## Interventions

- **DRUG:** Golimumab

## Key facts

- **NCT ID:** NCT03733925
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-11-15
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733925, "A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT03733925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*